To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-Vascular Risk Factor.

Trial Profile

To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-Vascular Risk Factor.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Telmisartan; Telmisartan/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRO-POWER
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 11 Mar 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.
    • 11 Mar 2011 Status changed from recruiting to completed reported by ClinicalTrials.gov.
    • 17 Aug 2010 Planned end date changed from 1 May 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top